myTomorrows Introduces Next-Generation AI Platform for Precision Trial Matching

What You Should Know:

–       myTomorrows, a global health technology company connecting patients and physicians with all possible pre-approval treatment options, today announced the launch of its next-generation AI platform.

–       Designed to streamline clinical trial recruitment, the platform supercharges how physicians search, pre-screen, and refer patients — helping trial sponsors accelerate enrollment, enhance diversity, and optimize operations.

Revolutionizing Clinical Trial Access with AI-Powered Precision

myTomorrows, a global healthtech company, is transforming access to clinical trials by leveraging proprietary AI-driven technology. By conducting comprehensive, real-time searches across global trial databases, the platform efficiently connects patients, physicians, trial sites, and BioPharma, streamlining and accelerating access to investigational treatments.

At the core of this innovation is myTomorrows’ AI pre-screening tool, which automates trial eligibility checks with 98% accuracy—surpassing industry benchmarks and outperforming medically trained users. With the rise of disease subtypes and increasingly complex eligibility criteria, clinical trial navigation has become a time-intensive challenge. Physicians struggle to identify suitable trials, while sponsors and trial sites face visibility and recruitment hurdles.

To address these challenges, myTomorrows offers a cutting-edge, multi-stakeholder platform that:

• Sources trials from global registries, including ClinicalTrials.gov, EudraCT, and ISRCTN.
• Matches patient medical data against trial inclusion/exclusion criteria with superhuman precision.
• Classifies trials as eligible or ineligible, reducing search time from hours to minutes.
• Integrates securely with EHRs, ensuring ISO 27001 certification and compliance with GDPR and HIPAA.
• Enables seamless referrals, allowing physicians to connect pre-screened patients to trial sites confidently.

“Physicians are committed to providing the best care for their patients, yet many lack the time to navigate the complex clinical trial landscape,” said Michel van Harten, MD, CEO of myTomorrows. “This gap results in increased workloads, lower enrollment success rates, and missed opportunities for patients. Our AI-powered platform removes barriers by streamlining trial searches, pre-screening, and referrals—all within a secure, end-to-end solution. Built as a foundation for future agentic AI applications, it represents a bold step toward the future of clinical trial access.”

Internal performance testing demonstrated the AI’s 98% accuracy across 9 disease areas and 490 trials, outperforming both medically trained users and the Harvard n2c2 benchmark. Additionally, the platform includes a real-time clinical trial data feature, offering insights into investigational drugs’ mechanisms of action, efficacy, and safety profiles.

Expanding Access and Industry Impact
myTomorrows is poised to transform the BioPharma landscape by enhancing physician precision, broadening patient access, and improving diversity in trial participation. The company will unveil its next-generation AI platform at the SCOPE Summit in Orlando, Florida, on February 6, 2025—a premier global event for clinical operations executives. The technology, powered by state-of-the-art LLMs, will showcase how physicians can instantly identify the most suitable trials and refer high-quality candidates to participating sites.

Beyond individual physicians, the platform will soon be available to enterprises, including hospitals, Clinical Research Organizations (CROs), patient advocacy groups, and healthtech companies. Its enterprise offering enables bulk screening of patient populations and seamless integration with existing industry workflows, further accelerating recruitment and operational efficiency.

“At myTomorrows, we are purpose-driven, committed to serving and connecting all stakeholders across the care continuum,” added Dr. van Harten. “Our technology unlocks immense efficiency gains while ensuring more qualified patients gain timely access to clinical trials.”